Currently, all RA patients starting DMARD therapy should be screened for HBV infection with HBsAg, anti-HBc and anti-HBs antibodies (Table 2).47,56 Such screening offers the opportunity of identifying susceptible patients, while vaccination should be offered in HBV negative patients (HBsAg-, anti-HBc-, anti-HBs-) who are at high risk for HBV exposure.56 Here, KRT88P is linked to rheumatoid arthritis.